Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Rheumatoid Arthritis

  Free Subscription


Articles published in Curr Opin Rheumatol

Retrieve available abstracts of 43 articles:
HTML format
Text format



Single Articles


    April 2018
  1. VAN DE SANDE MGH, van Vollenhoven RF
    Evolution of clinical trials for rheumatoid arthritis and spondyloarthritis.
    Curr Opin Rheumatol. 2018 Apr 24. doi: 10.1097/BOR.0000000000000516.
    PubMed     Text format     Abstract available


    March 2018
  2. SAKKAS LI, Bogdanos DP
    Multiple hit infection and autoimmunity: the dysbiotic microbiota-ACPA connection in rheumatoid arthritis.
    Curr Opin Rheumatol. 2018 Mar 13. doi: 10.1097/BOR.0000000000000503.
    PubMed     Text format     Abstract available


    February 2018
  3. GILES JT
    Getting personal: towards individualized management of rheumatoid arthritis.
    Curr Opin Rheumatol. 2018 Feb 19. doi: 10.1097/BOR.0000000000000499.
    PubMed     Text format    


  4. MAHAJAN TD, Mikuls TR
    Recent advances in the treatment of rheumatoid arthritis.
    Curr Opin Rheumatol. 2018 Feb 15. doi: 10.1097/BOR.0000000000000496.
    PubMed     Text format     Abstract available


  5. BONELLI M, Scheinecker C
    How does abatacept really work in rheumatoid arthritis?
    Curr Opin Rheumatol. 2018 Feb 3. doi: 10.1097/BOR.0000000000000491.
    PubMed     Text format     Abstract available


    January 2018
  6. REGIERER AC, Strangfeld A
    Rheumatoid arthritis treatment in patients with a history of cancer.
    Curr Opin Rheumatol. 2018 Jan 31. doi: 10.1097/BOR.0000000000000492.
    PubMed     Text format     Abstract available


  7. DEN BROEDER AA, van Herwaarden N, van den Bemt BJF
    Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts.
    Curr Opin Rheumatol. 2018 Jan 31. doi: 10.1097/BOR.0000000000000487.
    PubMed     Text format     Abstract available


  8. DIXON WG, Michaud K
    Using technology to support clinical care and research in rheumatoid arthritis.
    Curr Opin Rheumatol. 2018 Jan 23. doi: 10.1097/BOR.0000000000000485.
    PubMed     Text format     Abstract available


  9. BERGSTRA SA, Allaart CF
    What is the optimal target for treat-to-target strategies in rheumatoid arthritis?
    Curr Opin Rheumatol. 2018 Jan 19. doi: 10.1097/BOR.0000000000000484.
    PubMed     Text format     Abstract available


  10. SLOWIKOWSKI K, Wei K, Brenner MB, Raychaudhuri S, et al
    Functional genomics of stromal cells in chronic inflammatory diseases.
    Curr Opin Rheumatol. 2018;30:65-71.
    PubMed     Text format     Abstract available


    December 2017
  11. RIDGLEY LA, Anderson AE, Pratt AG
    What are the dominant cytokines in early rheumatoid arthritis?
    Curr Opin Rheumatol. 2017 Dec 4. doi: 10.1097/BOR.0000000000000470.
    PubMed     Text format     Abstract available


    September 2017
  12. DARRAH E, Andrade F
    Rheumatoid arthritis and citrullination.
    Curr Opin Rheumatol. 2017 Sep 21. doi: 10.1097/BOR.0000000000000452.
    PubMed     Text format     Abstract available


    July 2017
  13. BOGDANOS DP, Sakkas LI
    From microbiome to infectome in autoimmunity.
    Curr Opin Rheumatol. 2017;29:369-373.
    PubMed     Text format     Abstract available


  14. RAYCHAUDHURI SK, Raychaudhuri SP
    Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis.
    Curr Opin Rheumatol. 2017;29:311-316.
    PubMed     Text format     Abstract available


  15. TANAY A
    Chikungunya virus and autoimmunity.
    Curr Opin Rheumatol. 2017;29:389-393.
    PubMed     Text format     Abstract available


  16. WANG Z, Chang C, Lu Q
    Epigenetics of CD4+ T cells in autoimmune diseases.
    Curr Opin Rheumatol. 2017;29:361-368.
    PubMed     Text format     Abstract available


    April 2017
  17. BRAGAZZI NL, Watad A, Neumann SG, Simon M, et al
    Vitamin D and rheumatoid arthritis: an ongoing mystery.
    Curr Opin Rheumatol. 2017 Apr 29. doi: 10.1097/BOR.0000000000000397.
    PubMed     Text format     Abstract available


  18. ATZENI F, Masala IF, di Franco M, Sarzi-Puttini P, et al
    Infections in rheumatoid arthritis.
    Curr Opin Rheumatol. 2017 Apr 18. doi: 10.1097/BOR.0000000000000389.
    PubMed     Text format     Abstract available


    March 2017
  19. COHEN S, Kay J
    Biosimilars: implications for rheumatoid arthritis therapy.
    Curr Opin Rheumatol. 2017 Mar 16. doi: 10.1097/BOR.0000000000000379.
    PubMed     Text format     Abstract available


  20. HSIAO B, Fraenkel L
    Incorporating the patient's perspective in outcomes research.
    Curr Opin Rheumatol. 2017;29:144-149.
    PubMed     Text format     Abstract available


  21. VAN DER WOUDE D, Toes RE
    The contribution of autoantibodies to post-translationally modified proteins to inflammatory arthritis.
    Curr Opin Rheumatol. 2017;29:195-200.
    PubMed     Text format     Abstract available


  22. HAHN M, Frey S, Hueber AJ
    The novel interleukin-1 cytokine family members in inflammatory diseases.
    Curr Opin Rheumatol. 2017;29:208-213.
    PubMed     Text format     Abstract available


    February 2017
  23. JOHNSON C
    Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease.
    Curr Opin Rheumatol. 2017 Feb 15. doi: 10.1097/BOR.0000000000000380.
    PubMed     Text format     Abstract available


  24. MYASOEDOVA E
    Lipids and lipid changes with synthetic and biologic disease-modifying antirheumatic drug therapy in rheumatoid arthritis: implications for cardiovascular risk.
    Curr Opin Rheumatol. 2017 Feb 15. doi: 10.1097/BOR.0000000000000378.
    PubMed     Text format     Abstract available


  25. KATZ P
    Causes and consequences of fatigue in rheumatoid arthritis.
    Curr Opin Rheumatol. 2017 Feb 15. doi: 10.1097/BOR.0000000000000376.
    PubMed     Text format     Abstract available


    December 2016
  26. ANSBORO S, Roelofs AJ, De Bari C
    Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both?
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


    October 2016
  27. ENGLAND BR, Thiele GM, Mikuls TR
    Anticitrullinated protein antibodies: origin and role in the pathogenesis of rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  28. DOUGADOS M
    Comorbidities in rheumatoid arthritis.
    Curr Opin Rheumatol. 2016;28:282-8.
    PubMed     Text format     Abstract available


  29. MANKIA K, Emery P
    A new window of opportunity in rheumatoid arthritis: targeting at-risk individuals.
    Curr Opin Rheumatol. 2016;28:260-6.
    PubMed     Text format     Abstract available


  30. KADO R, Sanders G, McCune WJ
    Suppression of normal immune responses after treatment with rituximab.
    Curr Opin Rheumatol. 2016;28:251-8.
    PubMed     Text format     Abstract available


    March 2016
  31. LANDEWE R, van der Heijde D
    New concepts of clinical trials in rheumatoid arthritis: a boom of noninferiority trials.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  32. FRIEDMAN MA, Winthrop K
    Vaccinations for rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  33. NAM JL
    Rheumatoid arthritis management of early disease.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  34. VAN DER GOES MC, Jacobs JW, Bijlsma JW
    Rediscovering the therapeutic use of glucocorticoids in rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  35. EMERY P
    Introduction: the future of rheumatoid arthritis management.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format    


  36. DEKKERS J, Toes RE, Huizinga TW, van der Woude D, et al
    The role of anticitrullinated protein antibodies in the early stages of rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available



  37. The lung in rheumatoid arthritis, cause or consequence? Erratum.
    Curr Opin Rheumatol. 2016;28:1.
    PubMed     Text format     Abstract available


  38. COSWAY E, Anderson G, Garside P, Prendergast C, et al
    The thymus and rheumatology: should we care?
    Curr Opin Rheumatol. 2016;28:189-95.
    PubMed     Text format     Abstract available


    February 2016
  39. IANCULESCU I, Weisman MH
    Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis?
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  40. MATHEW AJ, Danda D, Conaghan PG
    MRI and ultrasound in rheumatoid arthritis.
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


    January 2016
  41. CHEMIN K, Klareskog L, Malmstrom V
    Is rheumatoid arthritis an autoimmune disease?
    Curr Opin Rheumatol. 2016.
    PubMed     Text format     Abstract available


  42. CHATZIDIONISYOU A, Catrina AI
    The lung in rheumatoid arthritis, cause or consequence?
    Curr Opin Rheumatol. 2016;28:76-82.
    PubMed     Text format     Abstract available


    May 2015
  43. TOES RE, Huizinga TJ
    Update on autoantibodies to modified proteins.
    Curr Opin Rheumatol. 2015;27:262-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Rheumatoid Arthritis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: